Fused tricyclic compounds as adenosine receptor antagonist

US9006177B2 · kind B2 · utility

Assignee

• Advinus Therapeutics Limited

Inventors

• Dinesh Barawkar · Lake Forest, US
• Sujay Basu · Mumbai, IN
• Vidya Ramdas · Pune, IN
• Minakshi Naykodi · Pimpri-Chinchwad, IN
• Meena Patel · Libertyville, US
• Yogesh Shejul · Pimpri-Chinchwad, IN
• Sachin Thorat · Pimpri-Chinchwad, IN
• Anil Panmand · Pimpri-Chinchwad, IN

Key dates

• Filing date: Sep 22, 2011
• Grant date: Apr 14, 2015
• Expiry date: Sep 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, dr…